We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Greiner Bio-One

The Preanalytics division develops, manufactures and distributes venous blood collection devices for hospitals, labor... read more Featured Products: More products

Download Mobile App





Greiner Bio-One Introduces Next Generation Urine Diagnostics

By LabMedica International staff writers
Posted on 29 Jul 2025

Greiner Bio-One (Kremsmünster, Austria) is exhibiting its latest advancements at ADLM 2025, which also marks the debut of its new urinalysis tube that offers room-temperature sample stability up to 72 hours. More...

At ADLM 2025, Greiner Bio-One will debut the VACUETTE Urine STB tube, which offers a standardized solution to ensure the stability of urinalysis samples by ensuring sample integrity. The all-new VACUETTE Urine STB Tube stabilizes key parameters for dipstick testing, clinical chemistry, and urine sediment analysis for up to 72 hours without refrigeration. VACUETTE Urine STB tubes contain a preservative made up of ethylparaben, chlorhexidine, and sodium propionate to inhibit bacterial and yeast growth and ensure the reliability of urinalysis results. This means a slow or delayed processing time during transport and storage will not affect the sample when it comes to sample quality and reliable analysis results, preventing the risk of preanalytical errors. The vacuum in the tube enables the optimal ratio of specimen sample to preservative. The tubes are available with a round or conical bottom for easier manual processing of the urinary sediment for microscopy analysis.

Greiner Bio-One is also sponsoring an Industry Workshop presented by Prof. Ana-Maria Simundic on the value that labs can deliver through patient blood management. Hospitalized patients are at high risk for developing hospital-acquired anemia (HAA). This session will focus on the methods labs may use to minimize patient blood loss and reduce HAA risk. Attendees will learn about the current landscape of patient blood management, explore available strategies and tools for minimizing patient blood loss, and discover possible benefits that may be achieved by implementing patient blood management interventions.

Related Links:
Greiner Bio-One


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
New
Automated Immunoassay Analyzer
SuperFlex™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.